Febuxostat prevents gout flares in recent clinical trial
- Date:
- October 4, 2017
- Source:
- Wiley
- Summary:
- The drug febuxostat reduced gout flares in a double-blind, placebo-controlled study of 314 adults with early gout.
- Share:
As reported in the journal Arthritis & Rheumatology, the drug febuxostat reduced gout flares in a double-blind, placebo-controlled study of 314 adults with early gout. Febuxostat treatment also reduced synovitis -- or inflammation of the joint lining detected by MRI scanning -- over a 2-year period compared with placebo.
Febuxostat treats high urate in the blood of patients with gout.
"Current clinical practice guidelines do not recommend routine use of urate-lowering therapy for people after the first gout flare.
This study indicates that even for people who have had only 1 or 2 prior gout flares, urate-lowering therapy to reduce serum urate below 6mg/dL may have benefit in reducing future flares," said Dr. Nicola Dalbeth, lead author of the study.
Story Source:
Materials provided by Wiley. Note: Content may be edited for style and length.
Journal Reference:
- Nicola Dalbeth, Kenneth G. Saag, William E. Palmer, Hyon K. Choi, Barbara Hunt, Patricia A. MacDonald, Ulrich Thienel, Lhanoo Gunawardhana. Effects of Febuxostat in Early Gout: A Randomized, Double-blind, Placebo-controlled Study. Arthritis & Rheumatology, 2017; DOI: 10.1002/art.40233
Cite This Page: